Abstract: With increasing antibiotic resistance reported worldwide, there is a great interest in the development of new antibacterial agents for the treatment of severe skin and skin structure infections (SSSIs). SSSIs mainly involve Grampositive pathogens. Although many of older antibiotics remain effective, new drug development remains crucial owing to the increase in drug resistance among the major Gram-positive pathogens. Since 1999 new antibacterial agents have entered the market or are being evaluated in clinical trials for the treatment of SSSIs. These agents have novel mechanism of action and sufficient improvements in potency to overcome resistance. Linezolid, quinupristin-dalfopristin, daptomycin and tigecycline have been approved by the FDA for the treatment of SSSIs. Other antimicrobials (dalbavancin, oritavancin, telavancin) are currently in clinical development for this indication. This review focuses on the chemistry, microbiology, pharmacology, clinical efficacy and safety of several novel antibacterial agents for the treatment of SSSIs.
INTRODUCTION
Gram-positive bacteria (e.g. Staphylococcus aureus, Streptococcus pyogenes and Streptococcus agalactiae) are the main cause of skin and skin structure infections (SSSIs) [1] [2] [3] .
The terminology used for infections of skin and skin structures is often varied and confusing. SSSIs can be divided in uncomplicated (uSSSIs) or complicated (cSSSIs). USSSIs include such clinical entities as simple abscesses, impetigenous lesions, foruncles, and cellulitis. CSSSIs include soft tissue infections (STIs) such burns, major abscesses, infections of deeper soft tissues and other skin structure infections requiring significant surgical intervention along with antimicrobial drug therapy [2] .
Antimicrobial resistance among Gram-positive bacteria has increased significantly during the last decade, with methicillin resistance among S. aureus [4] [5] [6] [7] . Multiresistant bacteria (MRB) are involved in 1/5 of nosocomial infections and the 3/4 of the MRB are methicillin resistant S. aureus (MRSA) [8] . For many years, MRSA was considered a multi-drug-resistant pathogen associated with hospitals [9] . Recently, many studies have reported that MRSA is an emerging community-associated pathogen (CA-MRSA) [10, 11] . A recent study reported that skin and soft tissue infections (SSTIs) are more common in CA-MRSA cases than in nosocomial MRSA cases (75% versus 37%) [12] . The structural gene for methicillin resistance, mecA, encodes a novel penicillin binding protein (PBP)-2', which has reduced affinity for all -lactam agents [13] . For this reason, glycopeptide agents (vancomycin and teicoplanin) have been considered the only available antibiotics active against multidrugresistant staphylococci. Subsequently, the first vancomycinintermediately resistant S. aureus (VISA) isolate was identi *Address correspondence to this author at the Dipartimento Clinico e Sperimentale di Medicina e Farmacologia, Policlinico Universitario, Torre Biologica V piano, Via Consolare Valeria, 98125 Messina, Italia; Tel: ++39-090-2213649; Fax: ++39-090-2213300; E-mail: desarro@unime.it fied in Japan in 1997 [14] . More recently clinical strains of MRSA with reduced susceptibility to vancomycin or more generally to glycopeptides, and referred as VISA or glycopeptide-intermediate S. aureus (GISA), have been reported in several countries [15] [16] [17] . However, the first clinical isolate of vancomycin resistant S. aureus (VRSA) was reported from United States in 2002 [18] . More recently VRSA strains have been reported from various parts of the world [19] [20] [21] [22] . The emergence of antibiotic resistance among the pathogens most commonly associated with SSSIs (e.g. methicillin-and vancomycin-resistant S. aureus and macrolides-resistant S. pyogenes) has compromised treatment options and increased the incidence of treatment failure [3, 16, 23, 24] . The difficulty to treat the cSSSI caused from more resistant bacterial pathogens has created a need for different therapeutic agents. The response of the pharmaceutical industry is the development of new antibiotics which are highly active against these pathogens and have novel and diversified mechanisms of action. Newly approved options for the treatment of SSSIs include quinupristin-dalfopristin, linezolid and most recently daptomycin and tigecycline. This paper will review the potential role of novel FDA-approved investigational antimicrobial agents and will examine the status of some of those (dalbavancin, oritavancin, telavancin) that are currently under investigation. Table 1 provides information on the countries where these FDA licensed drugs are available with specific indications. Table 2 provides information about their pharmacological properties.
Introduction
Linezolid is the first member of a new class of antibiotics, the oxazolidinones, which was developed for the treatment of infectious diseases caused by Gram-positive pathogens. Licensed by the FDA in the year 2000, the approved indications for linezolid use include the treatment of SSSIs, caused by methicillin-susceptible S. aureus (MSSA) and MRSA, streptococci (S. pyogenes and S. agalactiae), in addition to other indications (e.g., nosocomial and communityacquired pneumonia and vancomycin-resistant Enterococcus fecium (VREF) infections) [25] [26] [27] . An additional indication approved in 2003 was for the treatment of diabetic foot infections caused by MSSA and MRSA [28] .
Chemistry and Mechanism of Action
Linezolid, is a 3-(fluorophenil)-2-oxazolidinone [26] . Studies on its mechanism suggest that linezolid inhibits protein synthesis at a very early step, likely preceding the interaction of formyl-methionyl transfer RNA and the 30S ribosome with the initiator codon [29] .
In Vitro Susceptibility Testing
In vitro studies have shown linezolid to be effective against many antibiotic resistant Gram-positive organisms, including MRSA, GISA and vancomycin-resistant enterococci (VRE) [30] [31] [32] [33] . The linezolid susceptible breakpoints defined by FDA and Clinical Laboratory Standards Institute (CLSI), formerly National Committee for Clinical Laboratory Standards (NCCLS), are 2 g/mL for Enterococcus spp., Streptococcus pneumonia and other Streptococcus spp., and 4 g/mL for Staphylococcus spp. [26] . Surveys have shown almost 100% susceptibility among staphylococci, including MRSA, enterococci and S. pyogenes [31, 34] . Tested against MRSA and MSSA strains collected from distinct part of the world, linezolid had MIC 90 ranging from [1] [2] [3] [4] g/mL [35, 36] . In a recent study, linezolid and several comparison Gram-positive focused agents were tested against 7971 Gram-positive isolates [37] . A total of 98% of linezolid MIC values were between 0.5 and 2 g/mL. Linezolid resistance was detected in only 4 isolates (0.05%) [37] . g/mL) [38] . Linezolid is primarily a bacteriostatic against most susceptible organisms but has shown bactericidal activity against some strains of S. pneumonia [39] .
Mechanism of Resistance
The only resistance mechanism described for linezolid is target modification. Most mutations defined in various species associated with linezolid resistance occur by guanosine to uracil substitution in the peptidyl transferase centre of 23S rRNA [40, 41] . These mutations were shown to decrease the oxazolidinone binding to the ribosome [42] . Studies into the mechanism of resistance have shown little evidence of spontaneous resistance development in S. aureus [43] . However, in vivo development of resistance to linezolid has been described for VREF and MRSA in patients who have received linezolid therapy [44] [45] [46] [47] [48] [49] [50] [51] . Point mutations in the gene encoding for the 23S bacterial ribosome appear to be the mechanism in acquired resistance to linezolid in both enterococci and staphylococci [44, 52] . A recent study has demonstrated linezolid's lack of cross-resistance with other protein synthesis inhibitors (including macrolides, chloramphenicol, lincosamides, aminoglycosides, streptogramins, tetracyclines) [53] . The ability of linezolid to circumvent multidrugresistance is the result of its novel mechanism of action. 
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Pharmacokinetics
A major advantage of linezolid is that it is available in both oral and parenteral formulations. Linezolid is rapidly and extensively adsorbed after oral administration, reaching the maximum plasma concentration (C max ) within 1-2 h and having an average bioavailability of 100% [26] . Plasma protein binding has been estimated to be 31%. The drug has a steady-state volume of distribution of about 30-50 L with adequate to good tissue penetration into skin blister fluids, bone, muscle, fat, alveolar cells, lung extracellular lining fluid and cerebrospinal fluid [54] . For doses in the range of 100 to 400 mg, proportional increases in the area under the plasma concentration-time curve (AUC) and C max have been observed [54] . Concomitant administration of food significantly reduced the C max of linezolid although the AUC was not affected [32] . Linezolid is primarily metabolized by oxidation of the morpholine ring, which forms two inactive metabolites: aminoethoxyacetic acid metabolite (A) and hydroxyethyl glycine metabolite (B). Linezolid is predominantly excreted renally, with 80-85% found in the urine (30% parent compound, 40% metabolite A, and 10% metabolite B), 7-12% in feces [55, 56] .
Pharmacokinetic parameters of linezolid in adults are not altered by hepatic or renal dysfunction, age or sex to an extent requiring dose adjustment [57] .
Clinical Studies
There is considerable clinical experience with the use of linezolid in SSTIs in phase II and III clinical trials. In a randomized, double-blind study, the efficacy and the safety of linezolid and oxacillin-dicloxacillin in patients with SSTIs were compared [58] . A total of 826 hospitalized adult patients were randomized to receive 600 mg of linezolid intravenously (i.v.) every 12 hours (q12h) or oxacillin 2 g i.v. q6h; following sufficient clinical improvement, patients were switched to the respective oral agents (linezolid 600 mg orally q12h) or dicloxacillin (500 mg orally q6h). Concomitant aztreonam therapy was added when necessary. Most common etiologic agents were S. aureus, S. pyogenes and S. agalactiae [58] . In the intent-to-treat (ITT) population, the clinical cure rates at test-of-cure (TOC) visit were comparable in the two treatment groups, with 279 of 400 (69.8%) linezolid-treated patients and 272 of 419 (64.9%) oxacillindicloxacillin-treated patients achieving a clinical cure in the linezolid and oxacillin-dicloxacillin groups, respectively. In the clinically evaluable (CE) subset of patients there was 90% rate of cure in the linezolid group versus 85% in the oxacillin/dicloxacillin group. Microbiological success was similar (88% vs. 86%). Both agents were well tolerated [58] . In comparative trials, linezolid was equally effective as vancomycin in patients with SSTIs caused by MRSA and has also demonstrated efficacy in patients with SSTIs caused by VRE [59] . In the treatment of MRSA caused infections the efficacy of linezolid was also evaluated in a randomized, open-label comparison with vancomycin [25] . At the TOC visit, among evaluable patients with MRSA, there was no statistical difference between the 2 treatment groups with respect to clinical cure rates (73.2% of patients in the linezolid group and 73.1% in the vancomycin group) or micro- Recently, a randomized, controlled, multicenter study compared vancomycin and linezolid for the treatment of cSSTIs with MRSA as a leading pathogen [27] . Patients were randomized (1:1) to receive linezolid (600 mg) q12h either i.v. or orally, or vancomycin (1 g q12h i.v.). In the ITT population, 92.2% and 88.5% of patients treated with linezolid and vancomycin, respectively, were clinically cured at the TOC visit. Linezolid outcomes (88.6%) were superior to vancomycin outcomes (66.9%) at the TOC visit for patients with MRSA infections. This study showed that linezolid therapy is well tolerated, equivalent to vancomycin in treating cSSTIs, and more effective than vancomycin in the treatment of cSSTIs due to MRSA [27] .
Adverse Evens
Linezolid seems to be well tolerated [60] . The most frequently adverse events (AEs) reported with linezolid were diarrhea (incidence across studies 2.8%-11%), headache (0.5%-11.3%), and nausea (3.4%-9.6%) [26] . Less common AEs included tongue discoloration and fungal infections [26, 61] . Thrombocytopenia and a slight increased risk for anemia were evident at 2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression [62] . Due to an occurance of myelosuppressive events, it is advisable to monitor blood cell counts weekly in patients with underlying hematologic abnormalities or lower baseline values especially when treatment with linezolid exceeds 14 days. Concerns have recently been raised about linezolid possibly inducing different types of neuropathies when administered for several months [63, 64] .
Drug Interaction
The oral absorption of linezolid is not affected by the presence of antiacids [65] . Physical incompatibilities resulted when linezolid was administered with some drugs (e.g., amphotericin B, ceftriaxone, diazepam), so the recommendation is to administer it separately. Linezolid is a reversible nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for an interaction with adrenergic and serotonergic agents. Patients receiving linezolid need to avoid ingestion of large amounts of foods or beverages with high tyramine content [60] .
Dosage
The recommended dose of linezolid i.v. or orally is 600mg q12h for cSSSIs. However, uSSSI s can be treated successfully with 400mg q12h. The parenteral drug product should be administered by i.v. infusion over a period of 30 to 120 minutes. No dose adjustment is necessary when switching from i.v. to oral therapy [60] . The maximum dosage for infants and children is 10mg/kg q8-12h. The duration of the treatment for skin infections is 10-14 days. Considering the high oral bioavailability of linezolid which distinguishes it from vancomycin, the patients treated with linezolid for cSSSIs can reduce i.v. therapy or take a full course of oral therapy. The ease of switching patients from i.v. to oral line-
Introduction
Quinupristin-dalfopristin was the first injectable streptogramin antibiotic approved in the USA for VREF bacteremia and cSSSIs caused by MRSA or S. pyogenes [70] [71] [72] . In the last few years, growing clinical evidence has indicated that quinupristin-dalfopristin may be a useful antimicrobial alternative for the treatment of various serious infections caused by Gram-positive bacteria in patients who failed or were intolerant of glycopeptide therapy [73] [74] [75] .
Chemistry and Mechanism of Action
Quinupristin-dalfopristin belongs to the streptogramins family. Dalfopristin is a derivative of a group A streptogramin and quinupristin is a derivative of a group B streptogramin. These two water-soluble streptogramins have been combined in a commercially available injectable form 30:70 (w/w) [71, 73] . Individually, quinupristin and dalfopristin demonstrate only modest in vitro bacteriostatic activity. However, the combination of these antibiotics commonly produces in vitro bactericidal activity 8 to 16 times higher than the sum of each individual component's activity against many Gram-positive organisms [76] .
Quinupristin and dalfopristin act synergically and bind irreversibly on the 50S ribosome to inhibit early and late phase protein synthesis. In particular, quinupristin blocks binding of aminoacyl-tRNA complexes to the ribosome whilst dalfopristin inhibits peptide bond formation and distorts the ribosome, promoting the binding of quinupristin. Consequently, incomplete peptide chains are released. The compromised transfer RNA interrupts protein synthesis, resulting in cell death [77] .
In Vitro Susceptibility Testing
Quinupristin-dalfopristin has an excellent in vitro activity against Gram-positive organisms most frequently encountered in SSSIs, including S. aureus and S. pyogenes. The criteria of the NCCLS (at present CLSI) for susceptibility, intermediate susceptibility, and resistance to quinupristindalfopristin are 1, 2, and 4 g/mL, respectively [78]. MIC s for most staphylococci, streptococci, pneumococci and E. fecium are from 0.25 to 2 g/mL [77, 79] . Furthermore, quinupristin-dalfopristin has an activity against most methicillin-, lincosamide-and erythromycin-resistant strains of coagulase-negative staphylococci (CoNS) and S. aureus (MIC 90 0.5 and 1 g/mL, respectively) [80] . The drug is also active (MIC 90 1 g/mL) against glycopeptide-resistant S. aureus [77] . Several studies have shown that the species Enterococcus fecalis has intrinsic resistance to this compound [81, 82] .
Mechanism of Resistance
Resistance to streptogramins occurs by at least three mechanisms: a) target modification that provides resistance to macrolides, lincosamides and streptogramin B and is conferred by the erm genes (as dalfopristin is a streptogramin A, which susceptibility to quinupristin-dalfopristin is not affected by this mechanism); b) drug-modification confers resistance to streptogramin A and is provided by genes vatD and vatE encode acetyltransferases; and c) an efflux mechanism mediated by an adenosine triphosphate-binding protein caused by the expression of the lsa gene that explains the intrinsic resistance E. fecalis [83, 84] .
Resistance to quinupristin-dalfopristin was expected to be a rare event. However, according to the SENTRY Antimicrobial Surveillance Program Report on Gram-positive organisms causing bloodstream infections, the resistance of E. fecium to this antibiotic went from 0% in 1997 to 16% in 1999 (12.6% intermediate-resistant and 3.8% resistant) [85] .
Cross-resistance has not been reported between quinupristin-dalfopristin and glycopeptide, quinolone or -lactam antimicrobials [80] .
Pharmacokinetics
The drug has minimal oral absorption and is administered only i.v. Studies have demonstrated a linear correlation between the quinupristin-dalfopristin dose and AUC across a wide range of doses in healthy volunteers. I.v. administration of 9 or 10 doses of quinupristin-dalfopristin ranging from 1.4 to 29.3 mg/kg has yielded peak plasma concentrations of quinupristin ranging from 0.61 to 19.93 g/mL and of dalfopristin ranging from 0.54 to 6.9 g /mL [86] . The manufacturer's recommended i.v. dose of quinupristin-dalfopristin in adults is 7.5 mg/kg given over 60 minutes every q8h; this has consistently produced total C max of 11 to 12 g/mL, based on combined peak concentrations of quinupristin (3.2 ± 0.67 g/mL), dalfopristin (7.96 ± 1.30 g/mL), and their major metabolites [71, 86] .
Both quinupristin and dalfopristin undergo hepatic metabolism. Quinupristin has two primary active metabolites, and dalfopristin has a single major active metabolite [71] . The metabolites exert antibacterial activity similar to that of the parent compounds [87] . The parent drug and major metabolites are eliminated primarily by fecal excretion (75%), with a small portion of unchanged quinupristin and dalfopristin (15%-19%) eliminated renally [77] .
The elimination half-lives of both quinupristin and dalfopristin range from 0.70 to 1.53 hours [88] . The results of a pharmacokinetic study in patients with advanced liver disease and cirrhosis suggested that no pharmacokinetic alterations occurred in either parent drug, despite marked increases in the AUC of the drugs' individual metabolites [89] . However, no increase in AEs has been reported in patients with hepatic impairment [71] . In patients with renal impairment (creatinine clearance of < 30 mL/min), a 30% increase in the combined AUC of quinupristin-dalfopristin and their metabolites has been observed, but the manufacturer has not set guidelines for dosage reduction [71] . Finally, patients receiving continuous ambulatory peritoneal dialysis (CAPD) showed no significant alterations in the clearance of quinupristin-dalfopristin or the drugs' metabolites [90] .
Clinical Studies
Two randomized, open-label trials compared the efficacy and safety of quinupristin-dalfopristin versus standard comparators (cefazolin, oxacillin and vancomycin) in hospitalized patients with severe Gram-positive SSSIs. These investigations (one USA and one international trial) of virtually identical design enrolled a total of 893 patients (450 quinupristin-dalfopristin, 443 comparator) [91] . Patients treated with cefazolin, oxacillin, or vancomycin were combined in a single group for comparison with quinupristin-dalfopristin. The duration of antibiotic use ranged from 3 to 14 days. S. aureus was the most frequently isolated pathogen in both treatment groups and polymicrobial infection was more common in the quinupristin-dalfopristin group than in the comparator group. In the USA trial, patients were randomized to receive i.v. quinupristin-dalfopristin 7.5 mg/kg q12h or a comparator regimen of i.v. oxacillin 2 g q6h or vancomycin 1 g q12h. In the international trial, patients were randomized to receive i.v. quinupristin-dalfopristin 7.5 mg/kg q12h, cefazolin 1 g q8h, or vancomycin 1 g q12h. Unlike the USA trial, the international trial allowed the addition of aztreonam to either quinupristin-dalfopristin or comparator therapy [91] . The clinical success rate in the CE population was equivalent between the two treatment groups (68.2% quinupristin-dalfopristin, 70.7% comparator) despite a shorter mean duration of treatment for quinupristin-dalfopristin patients. In the bacteriologically evaluable population, by-patient and by-pathogen bacteriological eradication rates were lower for quinupristin-dalfopristin (65.8% and 66.6%, respectively) than for comparator regimens (72.7% and 77.7%, respectively). The lower bacteriological response rates in the quinupristin-dalfopristin group were, in part, due to a higher rate of polymicrobial infections the higher the incidence of patients classified as clinical failure, a category that included premature discontinuation of treatment because of local venous AEs. The bacteriological eradication rate for quinupristin-dalfopristin was higher in monomicrobial infections than in polymicrobial infections (72.6% versus 63.3%, respectively), whereas the corresponding rate for the comparator regimens was lower for monomicrobial infections than polymicrobial infections (70.8% versus 83.1%). The systemic tolerability of both treatment regimens was qualitatively similar. A higher rate of drug-related venous AEs was reported for quinupristin-dalfopristin (66.2%) than for comparator regimen (28.4%). Premature discontinuation of study drug was primarily due to adverse clinical events for quinupristin-dalfopristin (19.1%), whereas the most common reason for discontinuation among those receiving the comparator regimens was treatment failure (11.5%) [91] .
Adverse Events
The most frequently reported adverse effects with administration of quinupristin-dalfopristin (7.5 mg/kg i.v. q8h to q12h) were infusion-site reactions (e.g. inflammation, pain, and edema), thrombophlebitis and other infusion-site events. A deep catheter is usually required because this antibiotic causes severe irritation when given by peripheral vein. Administration through a central venous line is requested. Arthralgia, myalgia, nausea, diarrhea, vomiting, and rash are the most common systemic effects related to the drug. Arthralgia and myalgia have been reported to occur in about 10% of quinupristin dalfopristin-treated patients in noncomparative studies [92] . Although the mechanism of these AEs is unknown, they tend to be dose-related and reversible
N o t F o r D i s t r i b u t i o n
after drug discontinuation. These AEs are more likely to occur in patients with chronic liver disease and those who have received a liver transplant or are receiving cyclosporine or mycophenolate [93] . Furthermore, elevations in liver enzymes, increases in total and direct bilirubin, thrombocytopenia and decreases in hemoglobin have also been reported [71, 92] .
Interactions
Inhibits cytochrome P4503A4-mediated metabolism of drugs including midazolam, nifedipine, terfenadine and cyclosporin. Therefore, plasma drug monitoring and/or dosage reduction of these agents is prudent. However, concomitant administration of drugs that can prolong the electrocardiographic QTc interval should be avoided [71, 87, 92] . Limited experience with concomitant quinupristin-dalfopristin and cyclosporine has demonstrated a 2-fold increase in cyclosporine levels within 2 to 5 days of concomitant use [94] .
Dosage and Compatibility
The recommended dosage of quinupristin-dalfopristin for cSSSIs is 7.5 mg/kg given i.v. q12. The recommended minimum duration for the treatment of cSSSIs is seven days [71] . The dosage of quinupristin-dalfopristin does not have to be adjusted in elderly patients or patients with renal impairment. Limited clinical data are available on the use of the drug in patients with hepatic disease, but a dosage reduction may be required in patients with cirrhosis [71] . Quinupristindalfopristin is available in a single 500 mg vial. The recommended infusion volume and duration is 250 mL given over 60 minutes. Specific care should be taken to avoid saline and heparin flushes immediately before and after the drug administration. The manufacturer recommends that i.v. tubing be flushed with 5% glucose solution before and after infusion of quinupristin-dalfopristin. There are currently limited data concerning the compatibility of other drugs with quinupristin-dalfopristin [95] .
DAPTOMYCIN Introduction
Daptomycin is the first in a new class of cyclic lipopeptide agents derived from the fermentation of a strain of Streptomyces roseosporus [89] . The drug has been in clinical use in the USA since 2003 for treatment of cSSSI s caused by susceptible strains of the following Gram-positive organisms: S. aureus including MRSA, S. pyogenes, S. agalactiae, Streptococcus dysgalactiae subspecies equisimilis and E. fecalis (vancomycin-susceptible strains only) [96] [97] [98] [99] .
Chemistry and Mechanism of Action
Daptomycin is a cyclic lipopeptide comprising 13 aminoacids with a water-soluble hydrophilic core and a lipophilic tail [97, 100] . This structure is a key to its novel mode of action [101] . The lipophilic tail of daptomicin binds irreversibly to the cell membrane of Gram-positive bacteria via a calcium-dependent process [100, 101] . Calcium ions promote deeper insertion of daptomycin into the membrane by bridging the residual negatively charged aminoacids on daptomycin and the negatively charged phospholipids that are found in the cytoplasmic membrana of bacteria [102] . The proposed mechanism of action of daptomycin is believed to involve a multistep process in which membrane potential dissipation and the efflux of potassium out of the exposed bacterial cells, is the major event [100, 101] . This is followed by arrest of DNA, RNA and protein synthesis resulting in bacterial cell death. It seems possible that the collapse of the electrochemical gradient caused from the daptomycin would interfere with membrane-associated processes including synthesis of cell wall components, energetics and cell division [103] .
In Vitro Susceptibility Testing
Daptomycin showed in vitro activity against a wide range of aerobic and anaerobic Gram-positive bacteria including multidrug-resistant strains [30, [104] [105] [106] [107] . A daptomycin susceptible breakpoint is 1 g/mL for staphylococci and ß-hemolytic streptococci, whereas 4 g/mL for enterococci, as recently approved by CLSI [108] . The MIC 90 values for daptomycin against MSSA and MRSA isolates were 1 g/mL [106, 107, [109] [110] [111] [112] . Daptomycin demonstrated potency against the recently isolated VRSA as well as linezolid and quinupristin-dalfopristin-resistant S. aureus and E. fecium [107, 111, 113, 114] . In addition numerous GISA isolates were susceptible to daptomycin with MIC s of 0.13-1.0 g/mL [30, 113] . Furthermore, daptomycin is also effective against a variety of streptococcal groups such as the ß-hemolytic streptococci including S. pyogenes and S. agalactiae as well as other Streptococcus spp. [104, 114, 115] . Daptomycin has shown potent bactericidal activity in vitro. The bactericidal effect of daptomycin is rapid-greater than 99.9% of MRSA and MSSA bacteria die in less than 1 hour post treatment [116, 117] . Drug synergy with daptomycin has been described in vitro with aminoglycosides and rifampicin antibiotics [118, 119] . Antagonism between daptomycin and other antibiotics has not been seen [120] . A concentration-dependent post-antibiotic effect (PAE) has also been observed with daptomycin, lasting up to 6.3 and 6.7 h against S. aureus and E. fecalis, respectively, at clinically achievable concentrations [121] .
Mechanism of Resistance
Daptomycin's mechanism of action targets the cell membrane of Gram-positive bacteria, which typically has a relatively slow rate of inheriting resistance compared, for example, with agents targeting ribosomal RNA [100] . In vitro studies have shown a lack of propensity for spontaneous resistant mutants to arise; no transferable resistance elements have been identified [122] . However, stable S. aureus mutants were isolated by both serial passage in liquid media and chemical mutagenesis [123] . The daptomycin MICs for these isolates were 8-to 32-fold higher than for the parental strain. The bacterial membrane potential was increased in three independent resistant isolates. The potential mechanism of resistance patterns supported an alteration of membrane potential, which causes reduced binding of daptomycin [122] . In a recent study Kaatz et al . assessed that reduced binding of daptomycin to its target correlates with its resistance, possibly as a result of the loss of a membrane protein "chaperone" with which daptomycin interacts [124] . More recently, reports of Gram-positive strains with reduced susceptibility
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to daptomycin arising during therapy have begun to appear [125, 126] . Because of daptomycin's unique mechanism of action, the development of cross-resistance between daptomycin and other antimicrobial agents, such as glycopeptide or -lactam antibiotics appears unlikely [127] .
Pharmacokinetics
Daptomycin exhibits linear pharmacokinetics with minimal accumulation ( 20%) in healthy volunteers at doses up to 6 mg/kg, becoming slightly nonlinear at doses of 8 mg/kg in the AUC [128] . Its half-life ranged between 8 and 9 h, permitting dosing once per day. Daptomycin exhibits approximately 92% binding to plasma proteins, specially albumin. The low volume of distribution ( 0.1 L/kg) is due to its inability to cross cell membranes and its higher affinity for plasma proteins, as compared to tissue binding. Daptomycin is not extensively metabolized. It is excreted mainly in urine (78%), with approximately 50% of the active drug being recovered unchanged from urine within 24 h. A small proportion of daptomycin (6%) is also recovered in feces. Dosage adjustment is required in patients with severe renal insufficiency (creatinine clearances of < 30 mL/min). However, no such adjustment is necessary in patients with mild or moderate hepatic insufficiency [97, 128, 129] .
Clinical Studies
Two phase III clinical studies have been performed in patients with cSSSIs [130] . Both studies were randomized and evaluator blinded to compare the safety and efficacy of daptomycin with that of currently used antibiotics. Each phase III study involved approximately 500 patients (total population 1092 patients) with cSSSIs , associated or potentially associated with Gram-positive bacteria, including abscesses, surgical and traumatic wound infections and infected diabetic foot ulcers. Daptomycin 4 mg/kg i.v. oncedaily, administered as a 30-min infusion, was compared with vancomycin 1 g i.v. twice-daily, given as a 60-min infusion, or an oxacillin-class antibiotic (cloxacillin, flucloxacillin, oxacillin or nafcillin) 4-12 g i.v. once-daily, for 7-14 days. Aztreonam and/or metronidazole were added as deemed necessary. Daptomycin was demonstrated to be non-inferior to the comparator antibiotics, both in the individual and collective trials. For the combined ITT population (n = 1092) clinical success rates were 71.5% and 71.1% for daptomycin-and comparator-treated patients, respectively. Success rates in the CE population were 83.4% and 84.2%, respectively. Consistent efficacy, in terms of both clinical success and post-treatment relapse rates, was observed across predefined patient populations, Gram-positive species and all types of infection or infection sites. The duration of the treatment with daptomycin was shorter than with comparator antibiotics: the proportion of patients requiring only 4-7 days' therapy was 63% with daptomycin, vs. 33% with comparator therapy. In both phase III cSSSIs trials, daptomycin was well-tolerated, with the frequency and distribution of AEs being similar for patients receiving daptomycin (n = 534) and those given comparator antibiotics (n = 558). Most AEs were considered unrelated to the study medication and were of mild or moderate intensity. One or more drug-related AEs occurred in 18% of daptomycin-treated patients and in 21% of patients treated with comparator agents [130] .
Adverse Events
The most frequently experienced AEs in the phase III cSSSIs clinical trials were gastrointestinal disorders (e.g., constipation, nausea, diarrhea, injection site reactions, headache and rash). Treatment discontinuation due to AEs occurred for only 15 patients (2.8%) in the daptomycin group and 17 patients (2.8%) in the comparator group [130] . Given the potential for daptomycin-related muscle toxicity, as reported by Tally et al. creatine phosphokinase (CPK) levels were closely monitored in the phase III cSSTIs studies [130, 131] . Only 11 daptomycin-treated patients (2.1%) and 8 patients (1.4%) in the comparator group experienced muscle pain or weakness associated with CPK elevations, which resolved after the discontinuation of treatment with daptomycin. To date no drug-drug interactions are known.
Dosage
Daptomycin is only available as an i.v. agent. The recommended dosage for the treatment of cSSSIs is 4 mg/kg once q24h for patients with a creatinine clearance of 30 mL/min [97] . For patients with a creatinine clearance of < 30 mL/min, including patients receiving hemodialysis and CAPD, the recommended dosage is 4 mg/kg q48h [97, 129] . No dosage adjustment is recommended for patients with mild-to-moderate hepatic dysfunction [97] .
TIGECYCLINE Introduction
Tigecycline is the first of a new class of antimicrobials, the glycylcyclines, that was approved by FDA for the treatment of cSSSIs caused by resistant Gram-positive and Gramnegative bacteria on June 15, 2005 [132] .
Chemistry and Mechanism of Action
Similar to tetracyclines, tigecycline contains the central four-ring carbocyclic skeleton, with a substitution of an Nalkyl-glycylamido group at the D-9 position [133] . This substitution enables a broader spectrum of antimicrobial activity over the tetracyclines and allows defense against efflux pump and ribosomal protection mechanisms that otherwise confer tetracycline resistance [134] . Tigecycline's mechanism of action involves the inhibition of protein synthesis and cell growth in bacteria by reversible binding to A site of the 30S ribosomal subunit [134] [135] [136] [137] .
In Vitro Susceptibility Testing
Several reports have evaluated the in vitro activity of tigecycline against a wide range of bacterial pathogens commonly found in cSSSIs which includes MSSA, MRSA and VRE [138] . It has exhibited pronounced activity against pathogens that are susceptible and resistant to other antibiotics [113, [139] [140] [141] . Susceptibility breakpoint interpretations defined by FDA indicate that 0.5 g/ml is considered susceptible for S. aureus, 0.25 g/ml for Enterococcus fecalis (vancomycin-susceptible isolates only) and Streptococcus spp., and 0.4 g/ml for anaerobes [132] . MIC 90 values for tigecycline were uniformly low for most isolates including MRSA and MSSA (MIC 90 , 0.25-0.50 g/mL for both groups). No evidence of resistance was observed [138, 142] . Tigecycline is primarily bacteriostatic rather than bacteri-
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cidal [143] . The PAE of tigecycline was 3.4-4 h for strains of S. aureus and 1.8-2.9 h for strains of E. coli, including those carrying tet(M), tet(B), or tet(K) resistance determinants. For comparison, the PAE of minocycline ranged from 1 to 3 h for both S. aureus and Escherichia coli. These data indicate the potential for tigecycline to exert a significant antibacterial effect at sub-MIC concentrations [144] .
Mechanism of Resistance
Numerous tetracycline-resistant genes or tet(M) have been identified [145] . Some tet, genes code for efflux, whereas others influence ribosomal protection. As mentioned previously, tigecycline appears to overcome these mechanisms of resistance because of steric hindrance due to a large substituent at D-9 position. Tigecycline has shown an activity against organisms with plasmids containing either efflux or ribosomal protection genes [135, 137, 142] . This activity likely results from the inability of tigecycline to induce tetracycline efflux proteins or simply because the efflux pump is ineffective in transporting glycylcyclines out of the cell [134, 135] . In addition, the stronger binding affinity of tigecycline may interfere with the tet genes ability to bind effectively to the receptor and protect the ribosome. To date, attempts to create tigecycline resistant isolates in the laboratory using prolonged exposure to suboptimal concentrations of tigecycline have been unsuccessful [135] . In a recent study, Hirata et al. have examined the activity of tigecycline against E. coli strains harbouring plasmids encoding multidrug transporter genes, acrAB, acrEF and bcr [146] . Tigecycline MICs increased fourfold with strains producing these multidrug efflux proteins. Tigecycline appears to be a substrate of acrAB and acrAF which are resistance-modulationdivision type multicomponent efflux transporters [146] . Other reports have addressed the possibility of efflux pumps as the cause of reduced susceptibility to tigecycline in Proteus mirabilis, Pseudomonas aeruginosa and Escherichia coli [147, 148] .
Pharmacokinetics
Tigecycline requires intravenous administration. Studies on healthy volunteers demonstrated that tigecycline exhibited linear pharmacokinetics after single doses (range, 12.5-300 mg) and multiple doses (range, 50-200 mg) q12h [149] . Food increased the maximum tolerated single-dose from 100 to 200 mg, but the duration of infusion did not affect tolerability [150] . After a 1-h infusion, C max and AUC were dose proportional [149] . Tigecycline is highly protein bound (71%-87%) and has a large volume of distribution (7-10 L/kg) [149] . Concentrations of tigecycline in the gall bladder, lung and colon are higher than serum concentrations, while smaller increases were observed in the bone and synovial fluid. Concentrations of tigecycline in skin blister fluid have been found lower than serum concentrations [132, 151] . Tigecycline does not undergo extensive metabolism, but a slight amount is metabolized by liver glucuronidation [142] . Its elimination half-life is approximately 36 hours [132] . It is mainly excreted as unchanged drug and metabolites in the bile and feces (59%). Another 22% of the drug is excreted as unchanged drug in the urine [132, 137, 142, 149] . The pharmacokinetics of tigecycline in adults are not significantly altered by age, gender, or severe renal disease [152] .
Clinical Studies
Clinical efficacy of tigecycline has been demonstrated in cSSSIs. Postier et al. conducted a multicenter, randomized, dose-ranging study to assess the clinical efficacy and the safety of two doses of tigecycline for the treatment of cSSSIs in 160 hospitalized patients [153] . Patients received either 25 mg or 50 mg of tigecycline i.v. q12h for 7 to 14 days. Patients in the 25 mg group received a loading dose of 50 mg, and patients in the 50 mg group received a loading dose of 100 mg. At the end of therapy, 78% of CE patients in the 25 mg group and 85% of CE patients in the 50 mg group were considered cured. At the TOC visit, 67% of patients in the 25 mg group and 74% of patients in the 50 mg group were deemed clinically cured. At the end of therapy, bacterial eradication occurred in 62% of patients in the 25 mg group and 74% of patients in the 50 mg group. At the TOC visit bacterial eradication occurred in 56% of patients in the 25 mg group and 69% of patients in the 50 mg group [153] .
Adverse events were similar in both doses groups, with nausea and vomiting being the most common events. Rare laboratory abnormalities, including elevated serum levels of transaminases, alkaline phosphatase and blood urea nitrogen and anemia also occurred. This dose-ranging study showed that a loading dose (100 mg), followed by 50 mg i.v. q12h of tigecycline had higher rates of cure [153] .
Two large, randomized, multicenter, double-blind phase III studies have recently compared tigecycline monotherapy with the combination of vancomycin and aztreonam (V/A) [154, 155] . Patients received tigecycline 100 mg i.v. loading dose followed by 50 mg i.v. q12h. Vancomycin was given at a dose of 1g q12h and could be adjusted based on renal function. Aztreonam was given at a dose of 2 g i.v. q12h and could be discontinued after 48 hours at the investigator's discretion. Treatment was continued for up to 14 days in 1057 hospitalized patients with SSSIs [154, 155] .
The investigators assessed the clinical response in the clinical modified intent-to-treat (cmITT) and CE population at a predefinite TOC visit after the end of treatment, as well as the microbiologic response at the TOC visit. In addition, safety was assessed by physical examination, laboratory analyses, and AEs reporting.
Both studies showed no significant differences between either regimen in terms of clinical cure or microbiologic eradication rates.
As reported by Breedt et al. clinical responses in the tigecycline and the combination V/A groups were similar in the cmITT population (84.3% vs. 86.9%) and in the CE population (89.7% vs. 94.4%) [154] . Microbiologic eradication occurred in 84.8% of the patients receiving tigecycline and in 93.2% of the patients receiving the combination V/A. The number of patients reporting AEs was similar in the two groups, with increased nausea and vomiting rates in tigecycline group and an increased incidence of rash and increases in alanine aminotransferase and aspartate aminotransferase levels in the combination V/A group. Likewise Sacchidanand et al. reported that no significant differences were between either regimen in terms of clinical
N o t F o r D i s t r i b u t i o n
cure or microbiologic eradication rates. At the TOC, cure rates were similar between tigecycline and V/A groups in the CE population (82.9% vs. 82.3%, respectively) and in the c-ITT population (75.5% vs. 76.9%, respectively) [155] .
In the microbiologic evaluable population, eradication rates of selected isolates commonly associated with cSSSI were high in both treatment groups; for MRSA, eradication rates were 76.2% for the tigecycline group and 81.0% for the V/A group. Frequency of AEs similar between treatment groups, although patients receiving tigecycline had higher incidence of nausea, vomiting, dyspepsia and anorexia, while increases in alanine aminotransferase levels, pruritis and rash occurred significantly more often in V/A treated patients [155] .
Adverse Events
AEs reported with tigecycline are similar to those associated with tetracycline class as a whole [132] . Clinical trials reported nausea and vomiting as the most important AEs that, however, do not appear to lead to discontinuation of treatment. These events are thought to be caused by an irritant effect of tigecycline on the gastric mucosa [154, 155] . Other AEs included dyspepsia, diarrhea, headache, insomnia, dizziness, pain, fever, and anorexia. Mild elevation in liver function parameters and blood urea nitrogen were also observed, but required no intervention [132, 142] .
Interactions
Significant interaction has not been reported related to tigecycline. The pharmacokinetic and pharmacodynamic interactions between tigecycline and warfarin when administered concomitantly in healthy subjects have been assessed in an open-label, non-randomized two-period study. A trial was conducted with warfarin (single 25 mg dose), which demonstrated an increased C max of 38% (R-warfarin) and 43% (S-warfarin), with a corresponding increase in the AUC of 68% and 29%, respectively. There was no significant alteration in the coagulant profile of warfarin and warfarin administration did not alter the pharmacokinetic profile of tigecycline. Nevertheless it is suggested that anticoagulant monitoring is required in patients receiving warfarin. Similar to tetracyclines, caution is also warranted in patients receiving concomitant oral contraceptives, since decreased contraceptive efficacy may be the result otherwise [132] .
Dosage
The recommended dosage of tigecycline is 100 mg i.v. given as a loading dose, followed by 50 mg i.v. q12h administered as an infusion over 30-60 minutes [156] .
ANTIMICROBIALS CURRENTLY IN CLINICAL DEVELOPMENT FOR TREATMENT OF SKIN IN-FECTIONS Dalbavancin
Introduction
Dalbavancin is a novel glycopeptide antimicrobial currently in clinical development for the treatment of resistant Gram-positive organisms implicated in cSSSIs [157] .
Chemistry and Mechanism of Action
Dalbavancin is a semisynthetic lipoglycopeptide structurally related to teicoplanin. Differences from teicoplanin occur at apolipoproteins 1 and 3. Further differences occur with the number and positioning of the sugar moieties and chlorine molecules, as well as various methyl and hydroxyl groups [157] . Dalbavancin is similar to other glycopeptides in its mechanism of action, binding to the terminal alanyl-dalanine of nascent peptidoglycan chains and thus interfering with bacterial cell wall biosynthesis and resulting in cell death [158] .
In Vitro Susceptibility Testing
Dalbavancin studies showed a wide spectrum of activity against frequently isolated Gram-positive pathogens without regard to other resistance markers [159] [160] [161] . Dalbavancin most closely resembles teicoplanin in potency and spectrum; however, it is not more active than teicoplanin against VRE harboring the vanA phenotype of resistance to glycopeptides [162] . The excellent antistaphylococcal activity of dalbavancin includes MSSA, MRSA, VISA and CoNS [161, [163] [164] [165] [166] . Dalbavancin and selected comparators were tested against 6339 recent clinical isolates from worldwide sites [163] . The 99% of MIC results were at 1 g/mL S. aureus and CoNS were extremely susceptible to dalbavancin (MIC 90 , 0.06 g/mL) despite resistance patterns to other agents. Dalbavancin was the most potent compound against vancomycin-susceptible E. fecalis and E. fecium (MIC 90 , 0.06 and 0.12 g/mL, respectively); however, VRE strains showed decreased dalbavancin susceptibility (MIC 50 , 4 or 8 g/mL). All streptococcal isolates were inhibited at 0.25 g/mL of dalbavancin [163] . Another international survey tested a total of 7765 Gram-positive isolates against dalbavancin and 10 comparators agents [167] . The level of dalbavancin potency was greater than that of vancomycin (8-to 32 fold), linezolid (16-to 64 fold), teicoplanin (64-to 128 fold), and quinupristin-dalfopristin (8-to 32 fold). Dalbavancin (MIC 50 , 0.03-0.06 g/mL) was active against enterococci, except vanA resistance phenotypes [167] . Recently, dalbavancin exhibited greater potency in contrast to glycopeptides or lipopeptides, streptogramin combinations, and oxazolidinones against Gram-positive pathogens associated with SSSIs [168] . Dalbavancin (MIC 90 , 0.06-0.12 g/mL) was comparable in spectrum, but superior in potency to vancomycin (MIC 90 , 1-2 g/mL) against staphylococci. Dalbavancin MIC 90 value against the tested streptococci was 0.03 g/mL.
Dalbavancin was more active against tested SSTI pathogens than comparator agents having complete susceptibility rates (100%) similar to vancomycin [168] . To date, attempts to produce stable mutants with decreased susceptibility to dalbavancin in the laboratory have been unsuccessful [169] .
Pharmacokinetics
Dalbavancin is available only in an i.v. formulation. It has a significantly longer terminal half-life compared with that of the older glycopeptides [170] . Dalbavancin is highly protein bound (> 90%) and its terminal half-life in human subjects ranges from 149-250 hours [170, 171] . Such a pro-
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longed half-life supports the use of weekly dosing intervals when treating susceptible infections.
Prolonged plasma concentrations above 20 g/mL have been found after a single 1000 mg dose of dalbavancin even at one week after administration [171] [172] [173] .
By using a rat model, concentrations of dalbavancin in skin have been found to be equal to or greater than those in plasma, demonstrating good penetration into the peripheral compartments, which is essential in treating SSTIs [174] .
Dalbavancin is eliminated by both renal and non-renal routes [171] . It was excreted at 25-45.5% unchanged in urine, illustrating the need to consider non-renal elimination routes [171] .
Clinical Studies
In a phase II investigation of dalbavancin treatment for SSSIs, a 2-dose regimen (a 1000-mg dose given on day 1 followed by a 500-mg dose given on day 8) appeared to be well tolerated and to be more effective for the treatment of SSSIs due to Gram-positive bacteria, compared with either a single dose of dalbavancin regimen (1100 mg given on day 1) or investigator chosen standard of care. Comparator agents used were primarily -lactams, (ceftriaxone, cefazolin, piperacillin-tazobactam, and cephalexin) or vancomycin alone or in combination. Other comparators were linezolid and clindamycin [172] . S. aureus was the most prevalent species. The MIC 90 for the 25 baseline staphylococcal isolates was 0.12 g/mL. Clinical success rates at the TOC visit were 94.1% among patients treated with 2 doses of dalbavancin, 61.5% among patients treated with 1 dose of dalbavancin, and 76.2% among patients treated with a standardof-care regimen. All treatment regimens were well tolerated; drug-related AEs rates were similar across the 3 groups [172] .
More recently a multicenter, double-blind, randomized, phase III trial compared dalbavancin with linezolid for cSSSIs in 854 adult patients [175] . The dalbavancin dosage was 1000 mg i.v. on day 1 followed by 500 mg on day 8 (571 patients). The linezolid dosage was 600 mg twice/day i.v. or orally for a total of 14 days (283 patients). Approximately 90% of all pathogens isolated were S. aureus, of which a relatively high percentage (51%) was MRSA. All other pathogens were streptococcal species. The primary outcome was clinical success at the TOC visit. In the CE population, 88.9% and 91.2% achieved clinical success in the dalbavancin and linezolid arms, respectively. Microbiologic success rates at the TOC visit were similar between groups (89.5% and 87.5% for dalbavancin and linezolid, respectively). Overall, AEs events were similar between groups (25.4% for dalbavancin, 32.2% for linezolid) and most commonly involved nausea or diarrhea for both groups [175] .
Adverse Effects
A number of clinical trials have evaluated the efficacy and AEs events associated with dalbavancin. To date, AEs are mild and limited; the most common include pyrexia, headache, nausea, diarrhea or constipation, and oral candidiasis [171, 175] . Transient asymptomatic elevations of liver function tests occurred but did not require intervention [171, 175] . No clinically significant serum creatinine concentration abnormalities have been reported with the use of dalbavancin [171, 172, 175, 176] .
ORITAVANCIN Introduction
Oritavancin is a novel glycopeptide currently being developed for the treatment of cSSSIs, including those caused by multidrug resistant Gram-positive pathogens [136] .
Chemistry and Mechanism of Action
Oritavancin is an agent derived semi-synthetically from a precursor drug closely related to vancomycin. Although its mechanism of action is largely the same as that of vancomycin, there are sufficient differences such that it is active against vancomycin-resistant pathogens. Unlike vancomycin, oritavancin can dimerize (i.e., form paired associated molecules), leading to a cooperative interaction with the two stems of the growing peptidoglycan chain. The lipophilic side chain assists in membrane anchoring by hydrophobic interactions, stabilizing the dimer in the most favorable position. Also, evidence exists of another mechanism of action for oritavancin: inhibition of the transglycosylation step of cell-wall biosynthesis [177, 178] .
In Vitro Susceptibility Testing
The antibacterial spectrum of oritavancin includes S. pyogenes, S. pneumonia including penicillin-resistant isolates, staphylococci including MRSA and GISA, enterococci including VREF [179] . Most recently, oritavancin demonstrated extended activity against VRSA and enterococci [180, 181] . Oritavancin is not affected by the vanA, vanB and vanC-encoded alterations in the bacterial cell wall that impart vancomycin resistance [177] . Rapid bactericidal in vitro activity against most isolates of E. fecalis and E. fecium is a property of oritavancin that distinguishes it from vancomycin, ampicillin, linezolid, and quinupristin-dalfopristin [177, 182] .
Pharmacokinetics
The plasma pharmacokinetics of oritavancin have been evaluated in several single-and multiple-dose clinical pharmacology studies [136, 183] . The most salient pharmacokinetic property of oritavancin is its prolonged retention in the organism. Oritavancin displayed linear pharmacokinetics and an exceptionally long half-life (about 6-8 days). The plasma concentrations after a single infusion declined in a multiexponential manner over the 2-weeks [182] [183] [184] . The exceptionally long terminal half-life of oritavancin suggests the existence of storage sites within the organism. Studies in cultured macrophages indicate that the drug accumulates slowly in the lysosomes, from which its efflux is extremely slow [185] .
Clinical Studies
An open-label, uncontrolled, study has evaluated the pharmacokinetic profile and the safety of single doses of oritavancin administered i.v. to healthy subjects [183] . The drug displayed linear pharmacokinetics for weight-based
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doses ranging from 0.02 to 0.5 mg/kg of body weight. Oritavancin plasma concentrations after the end of infusion display a multiexponential decline over a 2-week period. Oritavancin displayed a long plasma terminal half-life (approximately 8 days), suggesting the drug accumulation will occur after multiple dosing. Less than 5% and 1% of administered drug were recovered in the urine and feces, respectively, after 7 days. No clinically relevant changes in renal, hepatic and hematologic indices were observed [183] .
Oritavancin has completed two phase III clinical trials for the treatment of cSSSIs [136] . Both studies compared 3-7 days of oritavancin (dosed with either 200 mg or 1.5 to 3 mg/kg once daily) to 3-7 days of vancomycin followed by oral cephalexin to complete 10-14 days of therapy. There was no difference in efficacy between the groups.
To evaluate the disposition of oritavancin in skin structures, oratavacin plasmatic levels were compared to those in the interstitial space fluids of soft tissue using a cantharideinduced blister fluid model [186] . Seventeen healthy male subjects received oritavancin, but only 16 subjects were evaluated. Each subject (eight per dose group) received 200 mg of oritavancin once a day for 3 days (group A) or 800 mg as one single dose (group B). Oritavancin levels were found maximal in blister fluid 10 h after dosing and decreased to undetectable levels 100 to 150 h after the last dose. The main observation of study has concerned the residence time of oritavancin in skin blister fluid. The most likely hypothesis involves macrophages, as oritavancin has been shown to be concentrated in macrophages, which migrate to inflamed tissues [185] . Furthermore, after administration of oritavancin at 200 mg once daily for 3 days or 800 mg as a single dose, blister fluid concentrations for total drug exceed the MIC 90 of oritavancin against S. aureus. Together, these findings support oritavancin as a valid therapeutic modality for cSSSIs [186] .
TELAVANCIN Introduction
Telavancin is a new glycopeptide antibacterial currently in phase III development for cSSSIs in the USA.
Chemistry and Mechanism of Action
It is a semisynthetic derivative of vancomycin. Like oritavancin, telavancin possesses a hydrophobic side chain on the vancosamine sugar and a substituent on the cyclic peptidic core [187] . The antibacterial effects of telavancin, are mediated through multiple mechanisms. Telavancin interacts with D-Ala-D-Ala-containing peptidoglycan intermediates that lead to inhibition of the transglycosylation step of peptidoglycan during cell wall synthesis [188, 189] . The drug also affects bacterial membrane functions, dissipating the membrane potential and effecting changes in cell permeability that correlate with loss in bacterial cell viability. This multiple mechanism of action may be responsible for the low frequency of spontaneous resistance to telavancin [190] .
In Vitro Susceptibility Testing
Telavancin displays rapid, bactericidal, concentrationdependent activity against clinically important Gram-positive aerobic pathogens, such as S. aureus (MSSA, MRSA, VISA and VRSA) [188] [189] [190] [191] [192] . The MIC 90 for both MRSA and MSSA was reported to be 1 g/mL for both strains [189] .
Pharmacokinetics
Currently, there are limited pharmacokinetic data available for telavancin [193] [194] [195] . Telavancin is only available as i.v. formulation. The pharmacokinetic profile of telavancin in plasma and blister fluid was studied in healthy subjects [195, 196] . Following the administration of multiple ascending doses the steady state was achieved by 3 to 4 days [196] . Peak telavancin concentrations in skin blister fluid lagged behind peak concentrations in plasma, but in both plasma and blister fluid adequate drug concentrations are achieved [195] . The plasma elimination half-life in subjects with normal renal function is 7-9 h [196] . Telavancin has a prolonged PAE (4-6 h) and a concentration dependent bactericidal activity [189, 195, 196] . Telavancin is primarily eliminated unmodified in the urine, and dose adjustment is needed in patients with renal failure [196] .
Clinical Studies
Recently two randomized, double-blind phase II trials (FAST and FAST2) have been conducted in patients with cSSSIs caused by Gram-positive bacteria, in which telavancin (7.5 or 10 mg/kg i.v. q24h) was compared with standard therapy (antistaphylococcal penicillin at 2 g q6h or vancomycin at 1 g q12h) [183, 184] . Results showed that clinical success rates were similar in all analysis population at TOC. In patients infected with MRSA, treatment with telavancin produced significantly higher bacterial eradication rates at TOC (92% vs. 68%) [184] . AE rates were also similar in the two treatment groups with mild and transient nausea, insomnia, headache and taste alterations occurring more commonly with telavancin treatment [194] .
These studies indicate telavancin's potential role as a treatment alternative for cSSSIs caused by resistant Grampositive pathogens.
CONCLUSIONS
Drug resistant Gram-positive bacteria are serious emerging problems in clinical practice because these organisms are common causes of a variety of SSSIs. Patients who have cSSSIs or whose infection is progressing despite empirical antibiotic therapy should be treated more aggressively and the treatment strategy must include agents with activity against resistant strains. Several new agents to combat these strains have been developed in recent years, linezolid, quinupristin-dalfopristin, daptomycin and tigecycline have already been approved by FDA for the treatment of SSSIs, whereas other agents like as dalbavancin, oritavancin, telavancin are still undergoing clinical trials. Treatment options are based on the antibacterial activity, resistance, pharmacokinetics, safety and cost. As a consequence, evaluation of new drugs is essential. Among new anti-Grampositive molecules linezolid seems attractive because of its potential for wider use, being an agent active not only against MRSA, VISA and VRE but also against important community-acquired pathogens such as S. pyogenes susceptible and resistant to macrolides. The availability of linezolid N o t F o r D i s t r i b u t i o n in i.v. and oral formulation provides an advantageous therapeutic approach for both outpatient and inpatient use. Thus, linezolid has the potential to reduce medical resource use through reducing the length of stay in hospital and reduced i.v. therapy, significantly lowering the treatment costs. Quinupristin-dalfopristin is an effective alternative for the treatment of hospitalized patients with cSSSIs due to quinupristin-dalfopristin susceptible Gram-positive organisms, including MRSA, erythromycin-resistant S. aureus and VRE. In seriously ill patients with unresponsive infections and minimal other potential treatment options, it should be considered the treatment of choice. However, its efficacy should be weighed against possible adverse effects, tolerability and interactions before using this potent antibiotic.
Daptomycin also has significant evidence for its favorable clinical profile. Its bactericidal activity against both growing and stationary-phase organisms suggests potential utility in the treatment of deep-seated infections. Tigecycline is an alternative agent available for the treatment of resistant Gram-negative and Gram-positive infections, especially in patients with a history of penicillin allergy or other antimicrobial-related toxicities. Tigecycline is typically bacteriostatic, rather than bactericidal. It is rapidly distributed and has extensive tissue penetration. Among the new lipoglycopeptides promising compounds are dalbavancin, oritavancin and telavancin. They are currently in advanced stages of clinical development. Their most salient property is the clinical relevance of pharmacokinetic/pharmacodynamic parameters that may be very important factors in clinical success. Due to its prolonged half-life, dalbavancin can be administered i.v. once weekly. This weekly regimen offers advantages such as improved patient compliance and reduced resource utilization compared with more frequently dosed agents.
Due to the continuing trend of increased resistance among Gram-positive organisms, it is very important to continue the development of new antibiotics. In order to limit the spread of antibiotic resistant pathogens, current and new antibiotic agents must be used appropriately. The safety profile of new antimicrobials also needs to be further assessed, especially for those molecules that are retained for prolonged times in an organism. A better understanding of where these agents belong in therapy should become more evident over the next few years. In the meantime, it is important to limit their use for the treatment of resistant infections or infections that recur despite adequate treatment with glycopeptides.
